Stock WAVE WAVERLEY PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Waverley Pharma Inc.

Equities

WAVE

CA94357L1058

Biotechnology & Medical Research

Market Closed - Toronto S.E.
Other stock markets
 12:31:26 2024-05-16 EDT 		5-day change 1st Jan Change
0.02 CAD 0.00% Intraday chart for Waverley Pharma Inc. 0.00% -20.00%
04-30 Waverley Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Waverley Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 15.12 5.4 6.75 4.32 1.62 1.35
Enterprise Value (EV) 1 12.18 3.923 6.08 4.424 2.188 2.899
P/E ratio -10.6 x -4.45 x -9.56 x -5.42 x -2.44 x -0.61 x
Yield - - - - - -
Capitalization / Revenue 67.7 x 4.67 x 4.91 x 2.46 x 1.3 x 3.28 x
EV / Revenue 54.5 x 3.39 x 4.42 x 2.52 x 1.75 x 7.03 x
EV / EBITDA - - -8,667,318 x -5,831,652 x -2,641,087 x -3,016,912 x
EV / FCF -29.7 x -3.47 x -12.1 x -7.92 x -5.01 x -3.62 x
FCF Yield -3.37% -28.8% -8.23% -12.6% -20% -27.6%
Price to Book 3.81 x 1.9 x 3.3 x 2.41 x 1.48 x -1.19 x
Nbr of stocks (in thousands) 54,000 54,000 54,000 54,000 54,000 54,000
Reference price 2 0.2800 0.1000 0.1250 0.0800 0.0300 0.0250
Announcement Date 19-04-29 20-05-13 21-04-26 22-04-29 23-04-27 24-04-29
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 0.2234 1.157 1.375 1.753 1.247 0.4121
EBITDA - - -0.7014 -0.7587 -0.8284 -0.9609
EBIT 1 -1.485 -1.414 -0.7096 -0.7868 -0.9361 -1.283
Operating Margin -664.6% -122.15% -51.6% -44.89% -75.08% -311.3%
Earnings before Tax (EBT) 1 -1.421 -1.215 -0.7058 -0.7965 -0.6641 -2.224
Net income 1 -1.421 -1.215 -0.7058 -0.7965 -0.6641 -2.224
Net margin -635.95% -104.97% -51.32% -45.44% -53.26% -539.7%
EPS 2 -0.0263 -0.0225 -0.0131 -0.0148 -0.0123 -0.0412
Free Cash Flow 1 -0.41 -1.131 -0.5006 -0.5583 -0.4366 -0.8003
FCF margin -183.51% -97.7% -36.4% -31.85% -35.02% -194.21%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 19-04-29 20-05-13 21-04-26 22-04-29 23-04-27 24-04-29
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - 0.1 0.57 1.55
Net Cash position 1 2.94 1.48 0.67 - - -
Leverage (Debt/EBITDA) - - - -0.1374 x -0.6856 x -1.612 x
Free Cash Flow 1 -0.41 -1.13 -0.5 -0.56 -0.44 -0.8
ROE (net income / shareholders' equity) -31.5% -35.6% -28.9% -41.6% -46.1% 9,743%
ROA (Net income/ Total Assets) -15.6% -18.3% -11.2% -13.7% -18.4% -44.1%
Assets 1 9.105 6.62 6.274 5.811 3.616 5.048
Book Value Per Share 2 0.0700 0.0500 0.0400 0.0300 0.0200 -0.0200
Cash Flow per Share 2 0.0500 0.0300 0.0100 0 0 0
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 19-04-29 20-05-13 21-04-26 22-04-29 23-04-27 24-04-29
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
WAVERLEY PHARMA INC. Stock Waverley Pharma Inc.
-20.00% 794K
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.42% 115B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.84% 106B
ARGENX SE Stock argenx SE
-1.05% 21.96B
BIONTECH SE Stock BioNTech SE
-14.15% 21.87B
GENMAB A/S Stock Genmab A/S
-5.29% 19.21B
BEIGENE, LTD. Stock BeiGene, Ltd.
-4.16% 18.08B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.29% 17.71B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.99% 14.32B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.24% 12.42B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. WAVE Stock
  4. Financials Waverley Pharma Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW